Every AI-ECG and AI-echo tool this cluster has reviewed individually fits into one of three broader screening pathway designs, and comparing the pathways rather than the individual products clarifies a question none of the single-product reviews can answer alone: given that AI-ECG is cheap and scalable but an indirect signal, and echocardiography is more informative but resource-intensive, which combination of the two, if any, makes the most sense for a given screening population and setting.
The three pathways, modelled
Pathway one: standard clinical assessment followed by selective echocardiography, the conventional approach, where a clinician's history, examination and risk assessment determine who proceeds to echo, with no AI-ECG layer involved. Pathway two: AI-ECG first, followed by echocardiography for patients flagged as high risk, using tools like Cardiovolt, EchoNext or Anumana to add a low-cost, scalable pre-screening layer ahead of the resource-intensive test, aiming to concentrate echo capacity on patients more likely to have disease. Pathway three: AI-guided point-of-care echocardiography first, using tools like Caption, UltraSight, Clarius or Us2.ai to extend ultrasound acquisition into settings and hands that would not otherwise have access to it, with formal comprehensive imaging reserved for uncertain or abnormal point-of-care findings, aiming to bring more of the diagnostic information directly to the first contact point rather than pre-filtering with an indirect ECG signal.
The comparison dimensions that decide between them
Test cost: pathway two adds a cheap pre-screening layer, pathway three adds a moderately more expensive but more informative acquisition step, and pathway one has the lowest direct testing cost but relies entirely on clinical judgement's own sensitivity. Disease prevalence in the screened population: the pathway comparison's most consequential variable, since AI-ECG pre-screening's value depends heavily on how well it discriminates at the prevalence actually encountered, exactly the arithmetic the evidence-literacy article's prevalence section makes explicit. Sensitivity and false-positive referrals: how many patients pathway two sends to echo unnecessarily, and how many patients pathway one's clinical judgement alone might miss entirely. Operator availability: pathway three's central constraint and central opportunity simultaneously, since it depends on point-of-care acquisition, guided by AI to lower the skill floor, but still requiring someone present to perform it. Time to definitive diagnosis: pathway three plausibly compresses this most directly, bringing informative imaging to first contact rather than requiring a separate referral step, while pathway two adds a layer before that referral step rather than replacing it. Incidental findings: any pathway that increases the number and sensitivity of tests performed increases the incidental-finding burden proportionally, the capacity question this cluster's dedicated analysis addresses in depth. Effect on formal echocardiography demand: pathway two aims to filter demand toward higher-probability patients; pathway three aims to reduce dependence on formal echo capacity for the uncertain-versus-clearly-normal-or-abnormal triage step specifically. Missed disease: the pathway design's ultimate failure mode, and one that depends on sensitivity at each stage compounding across the pathway rather than any single stage's sensitivity alone. And rural and underserved settings: arguably where the comparison matters most, since these are exactly the settings where standard pathway-one clinical assessment may have the least specialist backup, and where pathways two and three's scalability advantages could matter most, if their added complexity does not outstrip the local capacity to act on their outputs.
No single winner, by design
The honest conclusion this modelling exercise supports is that no single pathway is universally superior, because the right choice depends on the specific population's disease prevalence, the specific setting's operator and specialist availability, and the specific disease target's confirmatory-testing burden. A high-prevalence, symptomatic population with good echo access may gain little from an AI-ECG pre-screening layer that mainly adds a step before a test most of these patients would receive anyway. A low-prevalence, resource-constrained rural setting with limited sonographer access may gain considerably from either an AI-ECG filter that concentrates scarce echo capacity on the patients most likely to benefit, or an AI-guided point-of-care ultrasound layer that brings informative imaging to a setting that otherwise has none, and choosing between those two options for that specific setting is itself a modelling exercise worth running locally with real local prevalence and capacity figures rather than assumed from this article's general framework alone.
Frequently asked questions
Which pathway is cheapest overall?
Direct test cost favours pathway one, no additional AI-supported layer, though this ignores the cost of missed or delayed diagnosis that a well-targeted pre-screening layer might prevent, which is why cost comparisons need to account for downstream consequences, not only upfront testing expense.
Could a service run more than one pathway for different populations?
Plausibly and often sensibly: a service might reasonably apply an AI-ECG pre-screening layer to one population while deploying AI-guided point-of-care ultrasound in a different, access-constrained setting, since the pathways are not mutually exclusive design choices for an entire health system.
What local data would a service need to model this properly?
Its own population's disease prevalence for the target condition, its existing echo and sonographer capacity, and realistic sensitivity and false-positive figures for whichever specific AI tools are being considered, since generic published figures from a different population may not transfer directly to a local decision.